<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02597387</url>
  </required_header>
  <id_info>
    <org_study_id>CSPC-HE153/PRO/Ⅱ</org_study_id>
    <nct_id>NCT02597387</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Mitoxantrone HCL Liposome Injection in Patients With Relapsed DLBCL and PT/NKCLs</brief_title>
  <official_title>A Single-arm, Open, Multi-center Phase II Clinical Trial of Mitoxantrone HCL Liposome Injection in Subjects With Relapsed Diffuse Large B-cell Lymphoma and and Peripheral T/NK Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study efficacy and safety of Mitoxantrone HCL Liposome Injection in patients with diffuse&#xD;
      large B-cell lymphoma and lymphoma peripheral T cell.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Single-arm, Open, Multi-center Phase II Clinical Trial of Mitoxantrone HCL Liposome&#xD;
      Injection in Subjects With Relapsed Diffuse Large B-cell Lymphoma and and Peripheral T/NK&#xD;
      Lymphomas with dose of 20 mg/m2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR; complete response + partial response [CR + PR])</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Time from the date at which the patient's objective status is first noted to be a CR or PR to the earliest date progression is documented (assessed up to approximately 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Time from the date of registration to the date at which the patient's objective status is first noted to be a CR or PR (assessed up to approximately 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to a total of 24 months after first dose or until disease progression, withdrawal from study, or death</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Relapsed DLBCL and PT/NKCLs</condition>
  <arm_group>
    <arm_group_label>Mitoxantrone HCL Liposome Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each treatment cycle lasts for 28 days with 20mg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone HCL Liposome Injection</intervention_name>
    <arm_group_label>Mitoxantrone HCL Liposome Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subjects are voluntary and sign the informed consent form;&#xD;
&#xD;
          -  ECOG score 0 to 2;&#xD;
&#xD;
          -  The expected survival time ≥3 months;&#xD;
&#xD;
          -  Diffuse large B-cell and peripheral T/NK cell non-Hodgkin's lymphomas confirmed with&#xD;
             histopathology, and the peripheral T/NK cell lymphomas that are only limited to the&#xD;
             following types: peripheral T-cell lymphoma (not otherwise specified), angioimmunobl;&#xD;
&#xD;
          -  Failure or relapse after at least once of systemic treatment, and patients who can not&#xD;
             receive autologous peripheral blood stem cell transplantation&#xD;
&#xD;
          -  The major diameter of a single measurable lesion ≥1.5 cm in at least one measurable&#xD;
             lesion;&#xD;
&#xD;
          -  An interval of at least four weeks after the target tumor was treated with&#xD;
             chemotherapy, radiotherapy, biological therapy, stem cell transplantation or other&#xD;
             study drugs;&#xD;
&#xD;
          -  Subjects at childbearing age agree to take effective contraceptive measures during the&#xD;
             study; blood pregnancy test result is negative (except infertility due to menopause or&#xD;
             operation);&#xD;
&#xD;
          -  Laboratory tests (blood routine, liver and kidney function) meet the following&#xD;
             requirements:&#xD;
&#xD;
               -  ANC≥ 1.5×109/L, for those with bone marrow involvement, ANC ≥ 1.0×109/L;&#xD;
&#xD;
               -  PLT ≥ 75×109/L, for those with bone marrow involvement, PLT ≥ 50 × 109/L;&#xD;
&#xD;
               -  Hb ≥ 9 g/dL; d) Cr) ≤ 1.5x ULN ;&#xD;
&#xD;
               -  TBIL ≤ 1.5x ULN;&#xD;
&#xD;
               -  AST or ALT ≤2.5 x ULN (for patients with liver metastases, ≤ 5 x ULN ).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  An allergic history to anthracyclines or liposome drugs;&#xD;
&#xD;
          -  Disease progression or recurrence after anthracycline treatment within six months&#xD;
             before the enrollment;&quot;&#xD;
&#xD;
          -  Patients who once used mitoxantrone injection;&#xD;
&#xD;
          -  Patients who have used doxorubicin (or pirarubicin) with the total cumulative dose&gt;&#xD;
             360mg/m2, or epirubicin with the total cumulative dose &gt; 600mg/m2;&#xD;
&#xD;
          -  Left ventricular ejection fraction is &lt; 50% or &lt; the lower limit of normal; clinically&#xD;
             significant QT interval prolongation (&gt;450ms in male, &gt;470ms in female); a past&#xD;
             history of cardiac disease caused by anthracyclines; a history of severe heart&#xD;
             disease;&#xD;
&#xD;
          -  Concomitant treatment as other anticancer drugs are needed;&#xD;
&#xD;
          -  Lymphoma involving the central nervous system;&#xD;
&#xD;
          -  Clinically active infection that can significantly affect the clinical trial;&#xD;
&#xD;
          -  Within 6 weeks after organ transplantation or major organ surgery;&#xD;
&#xD;
          -  Those who are inappropriate to be enrolled as evaluated by the researchers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhu, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Zhu, Ph.D</last_name>
    <phone>+86 13910333346</phone>
    <email>zhujun@csco.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuqin Song, Ph.D</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mi Jiang, Ph.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>November 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2015</study_first_posted>
  <last_update_submitted>August 15, 2018</last_update_submitted>
  <last_update_submitted_qc>August 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

